Chordate Medical Holding AB (OSTO:CMH) 3-Year Revenue Growth Rate : -24.60% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB 3-Year Revenue Growth Rate?

Chordate Medical Holding AB's Revenue per Share for the three months ended in Mar. 2024 was kr0.00.

During the past 3 years, the average Revenue per Share Growth Rate was -24.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -52.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Chordate Medical Holding AB was 158.40% per year. The lowest was -68.20% per year. And the median was -40.15% per year.

Competitive Comparison of Chordate Medical Holding AB's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Chordate Medical Holding AB's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordate Medical Holding AB's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's 3-Year Revenue Growth Rate falls into.

Chordate Medical Holding AB 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Chordate Medical Holding AB (OSTO:CMH) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Chordate Medical Holding AB 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordate Medical Holding AB (OSTO:CMH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

K1Z:Germany

Address

c/o Regus, Kistagangen 20B, Kista, SWE, 164 40

Website

https://www.chordate.com

Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines